Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...
Vaccine
Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...
Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages
Ab&b Bio-Tech Co.,Ltd. (HKG: 2627) announced that the National Medical Products Administration (NMPA) has granted...
Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal
Novavax, Inc. (NASDAQ: NVAX) entered into a license agreement with Pfizer Inc. for non‑exclusive rights to...
AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
AIM Vaccine Co., Ltd (HKG: 6660) announced that China’s National Medical Products Administration (NMPA) has...
Kangtai Biological Co‑founds Beijing Laboratory to Advance Synthetic Immunology and Vaccine Manufacturing
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that its wholly‑owned subsidiary Minhai Biotechnology...
Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
Jiangsu Recbio Technology Co., Ltd. (HKG: 2179) announced that the New Drug Application (NDA) for...
Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform
Sanofi (NASDAQ: SNY) announced the completion of its $1.6 billion acquisition of Vicebio, first announced in...
Patronus Biotech Gates Foundation Grant Accelerates Malaria Vaccine Development
Patronus Biotech Pte. Ltd. announced it has received a grant from the Gates Foundation to...
Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine
Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum...
WestVac BioPharma & West China Hospital Secure NMPA Clearance for China’s First Acne Therapeutic Vaccine
WestVac BioPharma Co., Ltd. announced that the National Medical Products Administration (NMPA) has granted clinical‑trial...
BCHT Receives NMPA Approval for First Adult DTaP Vaccine Covering Pertussis, Diphtheria, and Tetanus
Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276) announced that its Adsorbed Acellular Pertussis (Two‑Component) Diphtheria...
Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution
Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn. Bhd. (wholly‑owned by Pharmaniaga Berhad) today announced a...
Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine
China‑based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with...
Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development
China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round,...
Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) today announced the signing of a technology‑transfer...
Chengdu Olymvax Biopharmaceuticals & Delonix Bioworks Announce Joint Development of Gene‑Engineered Pertussis Vaccine
Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and...
Maxvax Biotech Secures NMPA Acceptance for Its Recombinant Herpes Zoster Vaccine
Maxvax Biotech announced today that the China National Medical Products Administration (NMPA) has accepted the...
GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults
GlaxoSmithKline (NYSE: GSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval...
Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14
Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed...